All In Biotech

Drug Trial Radar · NCT06111586

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2b Study With a Blinded Extension and an Optional Open-label Extension-Assessing the Safety and Efficacy of Frexalimab, a CD40L-antagonist Monoclonal Antibody, for the Preservation of Pancreatic β-cell Function in Adults and Adolescents With Newly Diagnosed Type 1 Diabetes on Insulin Therapy

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 197 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

197

Actual

Start

Dec 11, 2023

Primary completion

Apr 28, 2027

Study completion Oct 29, 2030

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, parallel group, double-blind Phase 2 study with a blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. Study details include: Screening period: at least 3 weeks and up to 5 weeks. Enrollment date of the participant must take into consideration this constraint) Double-blind treatment period 104 weeks: Main treatment period: 52 weeks Blinded extension: 52 weeks Optional OLE period: 104 weeks Safety follow-up: 26 weeks The treatment duration will be up to 104 weeks , the total study duration will be up to 135 weeks for Part A and Part B. If participants enter the OLE period, the treatment duration will be up to approximately 208 weeks , and the total study duration will be 240 weeks approximately .

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • FrexalimabDrug

    IV Infusion at Day 1 SC Injection from W2 to W102

  • PlaceboDrug

    IV Infusion at Day 1 SC Injection from W2 to W102

  • InsulinDrug

    SC injection, dose and frequency will be established and/or adjusted by investigator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration, calculated from AUC from baseline to W52 for Part B (12-21 y.o.)Time frame: Baseline to Week 52

Locations

79 sites in 16 countries. Site status is shown where the registry gives one.

  • University of California San Francisco - Mission Bay- Site Number : 8400012

    San Francisco, California

  • University of Colorado - Anschutz Medical Campus- Site Number : 8400003

    Aurora, Colorado

  • University of Florida College of Medicine- Site Number : 8400010

    Gainesville, Florida

  • University of Miami Hospital- Site Number : 8400013

    Miami, Florida

  • AdventHealth Orlando- Site Number : 8400002

    Orlando, Florida

  • Rocky Mountain Diabetes and Osteoporosis Center- Site Number : 8400009

    Idaho Falls, Idaho

  • NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8400007

    Skokie, Illinois

  • Joslin Diabetes Center - Boston- Site Number : 8400015

    Boston, Massachusetts

  • University at Buffalo - Downtown Campus- Site Number : 8400004

    Buffalo, New York

  • University of North Carolina at Chapel Hill- Site Number : 8400001

    Chapel Hill, North Carolina

  • Cincinnati Children's Hospital Medical Center- Site Number : 8400019

    Cincinnati, Ohio

  • The Children's Hospital of Philadelphia Site Number : 8400005

    Philadelphia, Pennsylvania

  • University of Texas - Southwestern Medical Center- Site Number : 8400011

    Dallas, Texas

  • Benaroya Research Institute at Virginia Mason- Site Number : 8400016

    Seattle, Washington

  • Investigational Site Number : 0400002

    Graz, Austria

  • Investigational Site Number : 0400004

    Linz, Austria

  • Investigational Site Number : 0400001

    Vienna, Austria

  • Investigational Site Number : 0560002

    Brussels, Belgium

  • Investigational Site Number : 0560001

    Leuven, Belgium

  • Investigational Site Number : 1240001

    Vancouver, British Columbia, Canada

  • Investigational Site Number : 1240007

    London, Ontario, Canada

  • Investigational Site Number : 1240005

    Montreal, Quebec, Canada

  • Investigational Site Number : 1240004

    Montreal, Quebec, Canada

  • Investigational Site Number : 1240003

    Montreal, Quebec, Canada

  • Investigational Site Number : 2030003

    Ostrava, Czechia

  • Investigational Site Number : 2030002

    Prague, Czechia

  • Investigational Site Number : 2030001

    Prague, Czechia

  • Investigational Site Number : 2080005

    Herlev, Denmark

  • Investigational Site Number : 2460001

    Helsinki, Finland

  • Investigational Site Number : 2460004

    Oulu, Finland

  • Investigational Site Number : 2460003

    Tampere, Finland

  • Investigational Site Number : 2460002

    Turku, Finland

  • Investigational Site Number : 2500004

    Corbeil-Essonnes, France

  • Investigational Site Number : 2500005

    Mont-de-Marsan, France

  • Investigational Site Number : 2500006

    Paris, France

  • Investigational Site Number : 2500007

    Pontoise, France

  • Investigational Site Number : 2500003

    Saint-Herblain, France

  • Investigational Site Number : 2760003

    Dresden, Germany

  • Investigational Site Number : 2760001

    Hanover, Germany

  • Investigational Site Number : 2760002

    Oldenburg in Holstein, Germany

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.